Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.

Studied

A short review examined current and emerging medicines for adolescent obesity.

Who / model

Included evidence focused on randomized trials and meta-analyses in adolescents aged 12–18, with studies lasting more than 12 weeks. No pooled participant count is provided.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The review reports a 16.1% reduction in body mass index with semaglutide. It also identifies cost and unequal access as barriers.

Limits

Evidence for tirzepatide and CagriSema in adolescents remained limited. The authors call for longer-term, comparative and paediatric safety studies.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary